Showing 1716 results
-
Story /Novartis researchers are partnering with advocacy groups to understand the stigma and challenges facing patients with obesity.
-
Press release /SEG101 reduced annual rate of sickle cell-related pain crises (SCPC) by 45.3% compared to placebo in patients with or without hydroxyurea therapy SEG101 is a potential new disease-…
-
Press release /Basel, December 7, 2017 -Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S.A., a société anonyme organized under the laws of…
-
Press release /Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications Entresto (USD 84…
-
Story /From curiosity about life on Earth to transformative therapies at Novartis. Michelle L Krishnan, Executive Director, MD PhD.
-
Story /Novartis has launched a comprehensive research program to help find the right combinations of therapies for the right patients.
-
Story /Novartis is collaborating with Microsoft to apply machine learning to medicinal chemistry — part of an effort to leverage AI to bring treatments to patients more efficiently.
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRQ2 sales grew +9% (cc3, +7% USD) with core operating income growing +17% (cc, +9% USD)Innovative Medicines (IM) sales grew +9% (cc, +7% USD) and core…
-
Press release /Study in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint[1] Full results will be submitted for presentation at…